Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Tryptamine Therapeutics ( (AU:ENP) ) is now available.
Entropy Neurodynamics Limited has applied to the ASX for quotation of 762,195 fully paid ordinary shares, issued on April 17, 2026. These new shares were granted in lieu of cash payment for directors’ fees, following prior shareholder approval at the company’s November 13, 2025 annual general meeting.
The share-based remuneration reinforces the company’s focus on preserving cash while aligning directors’ interests more closely with those of shareholders. This move may modestly dilute existing holdings but signals confidence in the firm’s long-term value creation and supports capital management in a capital-intensive biotech and neurotechnology environment.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited, listed on the ASX under the code ENP, operates in the broader life sciences and neurotechnology sector. The company focuses on developing neurological therapies and related technologies, targeting investors interested in innovative approaches to brain health and neurodynamics-driven treatments.
Average Trading Volume: 2,293,449
Technical Sentiment Signal: Sell
Current Market Cap: A$47.3M
Find detailed analytics on ENP stock on TipRanks’ Stock Analysis page.